Efficacy of traditional Chinese medicine injection for diabetic kidney disease: A network meta analysis and systematic review

Background: Diabetic kidney disease (DKD) is an important public health problem worldwide that increases the mortality of patients and incurs high medical costs. Traditional Chinese Medicine injections (TCMIs) are widely used in clinical practice. However, their efficacy is unknown owing to a lack of definitive evidence. This study conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of traditional Chinese medicine injections in the treatment of DKD to provide a reference for clinical treatment. Methods: Total 7 databases had been searched, which included PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese scientific journal database (VIP), WanFang, and SinoMed. Only randomised controlled trials (RCT) had been included for analysis. The retrieval time limit was from the establishment of the database until 20 July 2022. Cochrane Risk of Bias 2.0 tool was used to evaluate the quality of the studies. Network meta-analyses, and Trial Sequential Analyses (TSA) were used to analysis the effectiveness of the included RCTs for DKD. The Stata 15.1 and R 4.0.4 were used to perform the network meta-analysis. Sensitivity analysis was used to assess the robustness of the findings. The effect of the intervention evidence are summarized on the basis of the minimum background framework. Results: NMA showed that the total effective rate of SMI, DCI, DHI, HQI, and SKI combined with alprostadil injection (PGE1) was better than PGE1 single used. Based on the surface under the cumulative ranking curve values, PGE1+DHI was the most effective for urinary albumin excretion rate and 24 h urinary albumin, PGE1+HQI was the most effective for the total response rate and β2-MG, and PGE1+SKI was the most effective for serum creatinine and blood urea nitrogen. Cluster analysis found that PGE1+HQI and PGE1+SKI could be the best treatments in terms of primary outcome measures. PGE1+SKI was found to be most effective on glomerular filtration function. PGE1+DHI was most effective for urinary protein-related indices. Conclusion: The efficacy of TCMI combined with PGE1 was higher than PGE1 single used. PGE1+HQI and PGE1+SKI were the most effective treatments. The safety of TCMI treatment should be investigated further. This study needs to be validated using large-sample, double-blind, multicentre RCTs. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=348333], identifier [CRD42022348333].

[1]  J. Pezzuto,et al.  Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research—The ConPhyMP—Guidelines , 2022, Frontiers in Pharmacology.

[2]  Jun Ai,et al.  Comparative Efficacy of Seven Chinese Patent Medicines for Early Diabetic Kidney Disease: A Bayesian Network Meta-Analysis. , 2022, Complementary therapies in medicine.

[3]  Hong-ping Xie,et al.  Danhong injection represses diabetic retinopathy and nephropathy advancement in diabetic mice by upregulating microRNA-30d-5p and targeting JAK1 , 2022, Bioengineered.

[4]  Jianling Mo,et al.  The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease. , 2022, Journal of ethnopharmacology.

[5]  Linhua Zhao,et al.  Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis. , 2022, Pharmacological research.

[6]  B. Duncan,et al.  IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.

[7]  Y. Wan,et al.  Inhibition of Renal Tubular Epithelial Mesenchymal Transition and Endoplasmic Reticulum Stress-Induced Apoptosis with Shenkang Injection Attenuates Diabetic Tubulopathy , 2021, Frontiers in Pharmacology.

[8]  Te Zhang,et al.  Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: A systematic review and meta-analysis. , 2021, Journal of ethnopharmacology.

[9]  Zhixiong Wang,et al.  Danhong injection alleviates cerebral ischemia/reperfusion injury by improving intracellular energy metabolism coupling in the ischemic penumbra. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Ning Wang,et al.  Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management , 2021, Acta pharmaceutica Sinica. B.

[11]  Yu He,et al.  Effect of main ingredients of Danhong Injection against oxidative stress induced autophagy injury via miR-19a/SIRT1 pathway in endothelial cells. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  Lingling Zhang,et al.  Tanshinone IIA Ameliorates Streptozotocin-Induced Diabetic Nephropathy, Partly by Attenuating PERK Pathway-Induced Fibrosis , 2020, Drug design, development and therapy.

[13]  Gordon H Guyatt,et al.  GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework , 2020, BMJ.

[14]  K. Khunti,et al.  Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline , 2020, Annals of Internal Medicine.

[15]  Junju Zou,et al.  A review on the efficacy and mechanism of action of Shenkang injection against chronic kidney disease. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  E. Mayo-Wilson,et al.  PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews , 2020, BMJ.

[17]  Franciele Q. Ames,et al.  Prostaglandin E1 prevents histopathological changes improving renal function in experimental nephropathy induced by renal microembolism. , 2020, International journal of clinical and experimental pathology.

[18]  L. Liao,et al.  Prostaglandin E1 attenuates high glucose-induced apoptosis in proximal renal tubular cells by inhibiting the JNK/Bim pathway , 2019, Acta Pharmacologica Sinica.

[19]  L. Liao,et al.  Prostaglandin E1 attenuates high glucose-induced apoptosis in proximal renal tubular cells by inhibiting the JNK/Bim pathway , 2019, Acta Pharmacologica Sinica.

[20]  Kyung Lee,et al.  Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes , 2019, Nature Communications.

[21]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[22]  Gordon H Guyatt,et al.  GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. , 2019, Journal of clinical epidemiology.

[23]  Lirong Lin,et al.  Preventive effect of Shenkang injection against high glucose-induced senescence of renal tubular cells , 2019, Frontiers of Medicine.

[24]  Xinzhong Huang,et al.  Salidroside stimulates the Sirt1/PGC-1α axis and ameliorates diabetic nephropathy in mice. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[25]  K. Morino,et al.  Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014 , 2019, Journal of diabetes investigation.

[26]  T. Ahluwalia,et al.  Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy , 2018, Diabetes Care.

[27]  E. Bonora,et al.  Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study , 2018, Acta Diabetologica.

[28]  R. Cooper,et al.  Increasing Mortality in Adults With Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria , 2018, Diabetes Care.

[29]  Ming Xu,et al.  Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy , 2018, Scientific Reports.

[30]  Ming Xu,et al.  Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy , 2018, Scientific Reports.

[31]  K. Tuttle,et al.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[32]  Rongshan Li,et al.  Are the Therapeutic Effects of Huangqi (Astragalus membranaceus) on Diabetic Nephropathy Correlated with Its Regulation of Macrophage iNOS Activity? , 2017, Journal of immunology research.

[33]  P. Han,et al.  Astragaloside IV ameliorates renal injury in db/db mice , 2016, Scientific Reports.

[34]  P. Heagerty,et al.  Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. , 2016, JAMA.

[35]  A. Wen,et al.  ShenKang injection suppresses kidney fibrosis and oxidative stress via transforming growth factor‐β/Smad3 signalling pathway in vivo and in vitro , 2015, The Journal of pharmacy and pharmacology.

[36]  Bu-chang Zhao,et al.  Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy , 2015, Scientific Reports.

[37]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.

[38]  Yi Zhang,et al.  A Review of Recent Research Progress on the Astragalus Genus , 2014, Molecules.

[39]  Mohammad Hassan Murad,et al.  A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis , 2014, BMJ : British Medical Journal.

[40]  R. Verpoorte,et al.  What is in a name? The need for accurate scientific nomenclature for plants. , 2014, Journal of ethnopharmacology.

[41]  Xiangdong Gao,et al.  Renoprotection of Danshen Injection on streptozotocin-induced diabetic rats, associated with tubular function and structure. , 2014, Journal of ethnopharmacology.

[42]  P. Tu,et al.  Extracts from Astragalus membranaceus limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia. , 2013, Journal of ethnopharmacology.

[43]  Chuanhua Yang,et al.  Astragaloside IV Stimulates Angiogenesis and Increases Nitric Oxide Accumulation via JAK2/STAT3 and ERK1/2 Pathway , 2013, Molecules.

[44]  L. Guarente,et al.  Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes , 2013, Nature Medicine.

[45]  Yang Ruan,et al.  Astragalus polysaccharides suppress ICAM-1 and VCAM-1 expression in TNF-α-treated human vascular endothelial cells by blocking NF-κB activation , 2013, Acta Pharmacologica Sinica.

[46]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.

[47]  R. Bilous,et al.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  J. Yue,et al.  Rheum officinale (a traditional Chinese medicine) for chronic kidney disease. , 2012, The Cochrane database of systematic reviews.

[49]  Xian-Guo Fu,et al.  [Effects of tanshinone IIA on Wnt/beta-catenin signaling pathway of high glucose induced renal tubular epithelial cell transdifferentiation]. , 2012, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[50]  Patrick J Heagerty,et al.  Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.

[51]  J. Yue,et al.  Prostaglandin E1 for preventing the progression of diabetic kidney disease. , 2010, The Cochrane database of systematic reviews.

[52]  S. Fava,et al.  The role of tubular injury in diabetic nephropathy. , 2009, European journal of internal medicine.

[53]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[54]  W. Cho,et al.  In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. , 2007, Journal of ethnopharmacology.

[55]  P. Hufnagl,et al.  Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-κB activation and adhesion molecule expression , 2003, Thrombosis and Haemostasis.

[56]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[57]  V. Alvaro,et al.  Best practice in research - Overcoming common challenges in phytopharmacological research. , 2020, Journal of ethnopharmacology.

[58]  Xiao-jun Zhou,et al.  Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells. , 2018, DNA and cell biology.

[59]  L. Fan.  Effects of Alprostadil Injection Combined with Danshen Injection on Early Diabetic Nephropathy , 2012 .

[60]  Gu Zhi-yuan.  Clinical observation on Suxuetong injection with prostaglandin E_1 for diabetic nephropathy , 2008 .